» Articles » PMID: 30732706

Long-Term Durability of Transcatheter Aortic Valve Prostheses

Abstract

Background: Very little is known about long-term valve durability after transcatheter aortic valve replacement (TAVR).

Objectives: This study sought to evaluate the incidence of structural valve degeneration (SVD) 5 to 10 years post-procedure.

Methods: Demographic, procedural, and in-hospital outcome data on patients who underwent TAVR from 2007 to 2011 were obtained from the U.K. TAVI (United Kingdom Transcatheter Aortic Valve Implantation) registry. Patients in whom echocardiographic data were available both at baseline and ≥5 years post-TAVR were included. Hemodynamic SVD was determined according to European task force committee guidelines.

Results: A total of 241 patients (79.3 ± 7.5 years of age; 46% female) with paired post-procedure and late echocardiographic follow-up (median 5.8 years, range 5 to 10 years) were included. A total of 149 patients (64%) were treated with a self-expandable valve and 80 (34.7%) with a balloon-expandable valve. Peak aortic valve gradient at follow-up was lower than post-procedure (17.1 vs. 19.1 mm Hg; p = 0.002). More patients had none/trivial aortic regurgitation (AR) (47.5% vs. 33%), and fewer had mild AR (42.5% vs. 57%) at follow-up (p = 0.02). There was 1 case (0.4%) of severe SVD 5.3 years after implantation (new severe AR). There were 21 cases (8.7%) of moderate SVD (mean 6.1 years post-implantation; range 4.9 to 8.6 years). Twelve of these (57%) were due to new AR and 9 (43%) to restenosis.

Conclusions: Long-term transcatheter aortic valve function is excellent. In the authors' study, 91% of patients remained free of SVD between 5 and 10 years post-implantation. The incidence of severe SVD was <1%. Moderate SVD occurred in 1 in 12 patients.

Citing Articles

The importance of tissue science and valve design in relation to durability and hemodynamics of the DurAVR aortic heart valve.

Neethling W, Forster G, Meduri C, Meuris B, Asgar A, Sellers S Front Cardiovasc Med. 2025; 12:1512961.

PMID: 39991635 PMC: 11842446. DOI: 10.3389/fcvm.2025.1512961.


The Evolving Role of the Multidisciplinary Heart Team in Aortic Stenosis.

Khan S, Shi W, Kaneko T, Baron S US Cardiol. 2024; 16:e19.

PMID: 39600833 PMC: 11588171. DOI: 10.15420/usc.2022.04.


Transcatheter Tricuspid Valve Replacement: Case Selection, Technical Considerations, and Procedural Planning.

Shabbir M, Yadav P, Tiwari N, Velagapudi P US Cardiol. 2024; 17:e11.

PMID: 39559523 PMC: 11571394. DOI: 10.15420/usc.2023.07.


Saudi Heart Association/National Heart Center/Saudi Arabian Cardiac Interventional Society/Saudi Society for Cardiac Surgeons/Saudi Cardiac Imaging Group 2023 TAVI Guidelines.

Albacker T, Tash A, Alamri H, Alasnag M, AlKashkari W, AlMutairi F J Saudi Heart Assoc. 2024; 36(2):184-231.

PMID: 39234557 PMC: 11373420. DOI: 10.37616/2212-5043.1379.


From an Unfolding Emergency Treatment to a Universal Shift in Therapy: The History and Evolution of the Catheter-Based Treatment of Aortic Valve Stenosis.

Agma H, Krull A, Feickert S, Ammareen R, Ince H, DAncona G Rev Cardiovasc Med. 2024; 23(10):349.

PMID: 39077143 PMC: 11267334. DOI: 10.31083/j.rcm2310349.